Clinical trials: Herpes Simplex Virus 2
Genital Herpes Simplex Type 2
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).
- Trial name
- NCT02030301
- Testing
- VCL-HB01, VCL-HM01, PBS
- Where
- 7 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Vical
HIV Infections, Herpesvirus 2, Human
Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are starting HIV treatment for the first time.
- Trial name
- NCT00371592
- Testing
- Acyclovir
- Where
- Peru
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women.
- Trial name
- NCT01386294
- Testing
- Tenofovir gel
- Where
- 9 sites in South Africa
- Volunteers
- 2,059 people, healthy volunteers welcome
- Sponsor
- CONRAD
HIV
An Assessment of an HIV Prevention Intervention (Project AIM) Among Junior Secondary School Students in Eastern Botswana
The purpose of this study is to examine the effectiveness of an HIV prevention intervention called Project AIM (Adult Identity Mentoring) to delay onset of sexual activity and reduce sexual risk behaviors among students…
- Trial name
- AIM (NCT02455583)
- Testing
- Project AIM (Adult Identity Mentoring)
- Where
- Botswana
- Volunteers
- 4,732 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered…
- Trial name
- NCT04762511
- Testing
- Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A)
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HSV-2
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00274300
- Testing
- pPJV7630 administered by PMED
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- PowderMed
Herpes Genitalis
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe.
- Trial name
- NCT04950712
- Testing
- Blood sampling, Anogenital lesion swab collection
- Where
- 51 sites in United States, Finland and 4 more
- Volunteers
- 537 people
- Sponsor
- GlaxoSmithKline
Genital Herpes
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
The primary objectives of the study are: To describe the safety profile of different investigational vaccine regimens against herpes simplex virus type 2 (HSV-2).
- Trial name
- HSV15 (NCT04222985)
- Testing
- HSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV
School Support as Structural HIV Prevention for Adolescent Orphans in Kenya
The purpose of this study is to test whether school support can keep adolescent Kenyan orphans in school, reduce sexual risk behaviors, and prevent HIV /HSV-2 infection.
- Trial name
- NCT01501864
- Testing
- School Support Intervention
- Where
- 2 sites in United States, Kenya
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- Pacific Institute for Research and Evaluation
Herpes Zoster, Neuralgia
Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)
The purpose of the study is to evaluate the safety and efficacy of NGX-4010 administered at intervals of no less than 12 weeks over 1 year, based on the presence or return of pain, for the treatment of painful HIV-AN and PHN.
- Conditions
- Herpes Zoster, Neuralgia, Pain, HIV Infections
- Trial name
- NCT00233155
- Testing
- Capsaicin Dermal Patch
- Volunteers
- 100 people
- Sponsor
- NeurogesX
Prophylaxis Herpes Simplex
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
The purpose of the study is to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and…
- Trial name
- NCT00698490
- Testing
- Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141, Herpes simplex virus containing gD-Alum
- Where
- Belgium
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster (HZ), Infectious Diseases
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
- Conditions
- Herpes Zoster (HZ), Infectious Diseases, Shingles
- Trial name
- NCT06581575
- Testing
- JCXH-105, Shingrix
- Where
- 8 sites in United States
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Postherpetic Neuralgia, Shingles
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
This study will evaluate the safety and efficacy of 2 weeks of topical KD7040 versus placebo in the treatment of postherpetic neuralgia.
- Conditions
- Postherpetic Neuralgia, Shingles, Herpes Zoster, Neuropathic Pain
- Trial name
- NCT00576108
- Testing
- KD7040 Topical Gel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Kalypsys, Inc.
HIV/AIDS, HSV-2 Infection
Cash Transfer to Adolescent Girls and Young Women to Reduce Sexual Risk Behavior - an Impact Evaluation
Vulnerability to HIV infection in Adolescent Girls and Young Women (AGYW) is mainly influenced by structural factors which mediate through sexual risk behavior.
- Trial name
- CARE (NCT03597243)
- Testing
- Cash Transfer
- Where
- Tanzania
- Volunteers
- 3,120 people
- Sponsor
- National Institute for Medical Research, Tanzania
Genital Herpes
HSV-2 Shedding Resolution After Acyclovir Treatment
The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated…
- Trial name
- NCT00495573
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Genital Herpes, HSV-2 Infection
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence.
- Trial name
- NCT03146403
- Testing
- GEN-003, Matrix-M2, 0.9% normal saline
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Genocea Biosciences, Inc.
Herpes Simplex
Herpevac Neonatal Substudy
The purpose of this study to look at the antibodies (proteins from the body's infection fighting system) in the blood of babies delivered by women who are participants in the Herpevac Trial for Women, and who were vaccinated with…
- Trial name
- NCT00138320
- Where
- 5 sites in United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
HSV-2 Infection, HIV Infections
Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa
The purpose of this study is to evaluate the impact of the new South African Department of Basic Education (DBE) sexuality and HIV education program that uses scripted lesson plans and supporting activities and will be…
- Conditions
- HSV-2 Infection, HIV Infections, Pregnancy Related
- Trial name
- NCT04205721
- Testing
- School-based sexuality and HIV prevention scripted lesson plans
- Where
- South Africa
- Volunteers
- 23,061 people
- Sponsor
- University of North Carolina, Chapel Hill
Genital Herpes Simplex Type 2
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
Randomized, double-blind, placebo-controlled, dose escalation study. There will be 3 cohorts of patients defined by the antigen dose (10, 30 or 100 µg of each antigen), and within each cohort, patients will be randomized at a…
- Trial name
- NCT01667341
- Testing
- GEN-003 with Matrix M-2, GEN-003
- Where
- 7 sites in United States
- Volunteers
- 143 people
- Sponsor
- Genocea Biosciences, Inc.